Publication:
Mineral metabolism and outcomes in chronic kidney disease stage 2-4 patients

dc.contributor.authorKamonwan Chartsrisaken_US
dc.contributor.authorKotcharat Vipattawaten_US
dc.contributor.authorMontira Assanathamen_US
dc.contributor.authorArkom Nongnuchen_US
dc.contributor.authorAtiporn Ingsathiten_US
dc.contributor.authorSomnuek Domrongkitchaipornen_US
dc.contributor.authorVasant Sumethkulen_US
dc.contributor.authorSinee Distha-Banchongen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-10-19T05:34:32Z
dc.date.available2018-10-19T05:34:32Z
dc.date.issued2013-01-17en_US
dc.description.abstractBackground: Marked hyperphosphatemia, hyperparathyroidism and 25-hydroxyvitamin D deficiency are associated with mortality in dialysis patients. Such data in chronic kidney disease stage 2-4 population are limited. It has been suggested that high-normal serum phosphate predicts worse renal and patient outcomes. The data regarding parathyroid hormone and outcomes in this population is limited. The present study examined mineral metabolism and its association with the development of end-stage renal disease and mortality in stage 2-4 chronic kidney disease patients. Methods. This is a prospective cohort study that included 466 non-dialysis chronic kidney disease stage 2-4 patients. Mineral parameters were obtained at the time of enrollment and the patients were followed prospectively for 25 (1-44) months or until they reached the endpoints of end-stage renal disease or mortality. Results: Hyperparathyroidism and 25-hydroxyvitamin D deficiency began to occur in the early stages of chronic kidney disease, whereas significant hyperphosphatemia only developed in the later stages. High-normal and mildly elevated serum phosphate (>4.2 mg/dL) predicted the composite outcome of end-stage renal disease or mortality after adjustments for cardiovascular risk factors, chronic kidney disease stage and other mineral parameters. Parathyroid hormone levels above the upper limit of normal (>65 pg/mL) predicted the future development of end-stage renal disease and the composite outcome of end-stage renal disease or mortality after adjustments. 25-hydroxyvitamin D deficiency (<15 ng/mL) was also associated with worse outcomes. Conclusions: In chronic kidney disease, hyperparathyroidism developed prior to significant hyperphosphatemia confirming the presence phosphate retention early in the course of chronic kidney disease. High-normal serum phosphate and mildly elevated parathyroid hormone levels predicted worse renal and patient outcomes. This data emphasizes the need for early intervention in the care of chronic kidney disease stage 2-4 patients. © 2013 Chartsrisak et al.en_US
dc.identifier.citationBMC Nephrology. Vol.14, No.1 (2013)en_US
dc.identifier.doi10.1186/1471-2369-14-14en_US
dc.identifier.issn14712369en_US
dc.identifier.other2-s2.0-84872175637en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/32570
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84872175637&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleMineral metabolism and outcomes in chronic kidney disease stage 2-4 patientsen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84872175637&origin=inwarden_US

Files

Collections